Latest filings (excl ownership)
424B3
Prospectus supplement
4 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
6-K
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to
1 Apr 24
POS AM
Prospectus update (post-effective amendment)
20 Mar 24
20-F
2023 FY
Annual report (foreign)
13 Mar 24
6-K
Sol-Gel Reports Full-Year 2023 Financial Results and 2023 - Corporate Highlights and Recent Developments
13 Mar 24
6-K
Important Notice to Shareholders Who Are United States Persons
6 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Current report (foreign)
23 Jan 24
6-K
Current report (foreign)
17 Jan 24
6-K
Current report (foreign)
30 Nov 23
6-K
Current report (foreign)
20 Nov 23
424B3
Prospectus supplement
9 Nov 23
6-K
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
424B3
Prospectus supplement
10 Aug 23
6-K
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
6-K
Current report (foreign)
27 Jul 23
6-K/A
Current report (foreign) (amended)
20 Jul 23
6-K
Notice of Annual Meeting of Shareholders
21 Jun 23
6-K
Current report (foreign)
14 Jun 23
6-K
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to
6 Jun 23
424B3
Prospectus supplement
12 May 23
6-K
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides
12 May 23
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
6-K
Current report (foreign)
30 Mar 23
UPLOAD
Letter from SEC
17 Mar 23
F-1
Registration statement (foreign)
10 Mar 23
S-8
Registration of securities for employees
10 Mar 23
20-F
2022 FY
Annual report (foreign)
10 Mar 23
6-K
Current report (foreign)
1 Mar 23
6-K/A
Current report (foreign) (amended)
21 Feb 23
6-K
Current report (foreign)
13 Feb 23
6-K
Current report (foreign)
2 Feb 23
6-K
Current report (foreign)
31 Jan 23
424B5
Prospectus supplement for primary offering
27 Jan 23
6-K
Current report (foreign)
27 Jan 23
6-K
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product
27 Jan 23
6-K
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
21 Nov 22
6-K
Sol-Gel Technologies Appoints Michael Glezin Vice
3 Oct 22
Latest ownership filings
SC 13D/A
Arkin Moshe
8 Apr 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Phoenix Holdings Ltd.
12 Feb 24
SC 13G
Migdal Insurance & Financial Holdings Ltd.
31 Jan 24
144
Notice of proposed sale of securities
28 Sep 23
144
Notice of proposed sale of securities
27 Sep 23
144
Notice of proposed sale of securities
26 Sep 23
144
Notice of proposed sale of securities
24 Jul 23
144
Notice of proposed sale of securities
27 Jun 23
144
Notice of proposed sale of securities
2 May 23
SC 13D/A
Arkin Moshe
20 Mar 23
SC 13G/A
Phoenix Holdings Ltd.
14 Feb 23
SC 13G
Migdal Insurance & Financial Holdings Ltd.
26 Jan 23
SC 13G/A
Phoenix Holdings Ltd.
7 Feb 22
SC 13G
Migdal Insurance & Financial Holdings Ltd.
2 Feb 22
SC 13G/A
Phoenix Holdings Ltd.
11 Feb 21
SC 13D/A
Arkin Moshe
20 Apr 20
SC 13G/A
Beneficial ownership report (amended)
18 Feb 20
SC 13G/A
Sol-Gel Technologies Ltd.
18 Sep 19
SC 13D/A
Sol-Gel Technologies Ltd.
21 Aug 19
SC 13G/A
Sol-Gel Technologies Ltd.
14 Feb 19
SC 13D
Sol-Gel Technologies Ltd.
12 Feb 18
SC 13G
Sol-Gel Technologies Ltd.
12 Feb 18